ROCKVILLE, Md. and SUZHOU, China, May 12, 2026
Ascentage Pharma announced that 17 major clinical advances across its hematology and oncology pipeline will be presented at the 31st Congress of the European Hematology Association (EHA2026), scheduled to take place in Stockholm, Sweden, from June 11 to 14, 2026. The company stated that the presentations will include eight scientific posters featuring updated data from ongoing clinical studies involving its core assets Olverembatinib (HQP1351) and Lisaftoclax (APG-2575), highlighting continued progress in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). The extensive EHA2026 presence reinforces Ascentage Pharma’s growing position within the global hematology therapeutics market as the company expands development of targeted cancer therapies and next-generation apoptosis pathway inhibitors.
Olverembatinib Expands Clinical Momentum in Leukemia Studies
One of the most important EHA2026 presentations will feature updated efficacy and safety findings evaluating Olverembatinib as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML). Olverembatinib is China’s first approved third-generation BCR-ABL inhibitor and has emerged as one of Ascentage Pharma’s most strategically important oncology assets. Additional studies being presented at EHA2026 will examine Olverembatinib’s effectiveness in heavily pretreated CML patients with prior resistance to Ponatinib or Asciminib, including patients carrying high-risk ASXL1 mutations associated with poor prognosis and treatment resistance. The company believes these findings may strengthen the therapeutic profile of Olverembatinib in difficult-to-treat leukemia populations where treatment options remain limited.
Ascentage Pharma will also present updated results from POLARIS-1, a global registrational Phase 3 trial evaluating Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study represents one of the company’s most advanced late-stage development programs outside China and forms part of a broader global regulatory strategy targeting multiple hematologic malignancies. Industry analysts believe Olverembatinib could become a significant competitor within the next-generation tyrosine kinase inhibitor market if ongoing global studies continue demonstrating durable efficacy and manageable safety profiles.
The company emphasized that Olverembatinib is already approved in China for multiple CML indications, including chronic-phase and accelerated-phase CML with T315I mutations, as well as CML resistant or intolerant to first- and second-generation TKIs. The therapy is currently included in China’s National Reimbursement Drug List (NRDL), supporting broader patient access. Ascentage is simultaneously conducting the FDA-cleared POLARIS-2 Phase 3 trial in chronic myeloid leukemia and additional registrational studies targeting gastrointestinal stromal tumors (GIST) and newly diagnosed Ph+ ALL patients, reflecting the company’s ambition to expand internationally beyond the Chinese oncology market.
Lisaftoclax Advances Global Development in Blood Cancers
Advertisement
Another major focus of EHA2026 will involve Lisaftoclax (APG-2575), Ascentage Pharma’s selective Bcl-2 inhibitor developed for treatment of hematologic malignancies. The company plans to present new analyses examining correlations between baseline disease characteristics and prognosis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with Lisaftoclax in a pivotal Phase 2 clinical study. Additional presentations will highlight early findings evaluating the combination of Olverembatinib and Lisaftoclax in pediatric patients with relapsed or refractory Ph+ ALL, an especially challenging leukemia subtype with high unmet medical need.
Lisaftoclax recently became the second approved product in Ascentage Pharma’s commercial portfolio after receiving approval in China for adult patients with previously treated CLL/SLL who had received prior systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The company is currently conducting four global registrational Phase 3 studies involving Lisaftoclax across CLL, AML, and high-risk MDS populations. These include the FDA-cleared GLORA study, which evaluates Lisaftoclax combined with BTK inhibitors in patients with suboptimal response following long-term BTK inhibitor therapy.
Ascentage Strengthens Global Oncology Development Strategy
The strong EHA2026 presence reflects Ascentage Pharma’s broader strategy to establish itself as a global oncology-focused biopharmaceutical company centered on apoptosis-targeting therapies, kinase inhibitors, and protein degradation technologies. In addition to Olverembatinib and Lisaftoclax, the company continues advancing multiple programs targeting Bcl-2, MDM2-p53, and other cancer-related signaling pathways. Ascentage has also established collaborations with several major pharmaceutical companies including AstraZeneca, Merck, Pfizer, and Takeda to support global development and commercialization initiatives.
The company stated that the latest EHA2026 presentations demonstrate continued progress toward expanding innovative treatment options for patients with difficult-to-treat hematologic cancers. As competition intensifies across targeted oncology therapeutics and next-generation blood cancer treatments, Ascentage aims to differentiate itself through globally scalable precision medicines supported by broad clinical development programs and international regulatory expansion strategies.
Source: Ascentage Pharma press release
